KV PHARMACEUTICAL CO.

Remarks in House

FDA: clarification of order approving the drug Makena for women at risk for preterm birth but denying Makena market exclusivity, H2050 [30MR]

Remarks in Senate

Pharmaceuticals: cost regulation of drug hormone, progesterone, to prevent premature births, S2800 [9MY]